CLYM17097 / S1608 / Paul BarrResearch Question:
What are the good and bad effects of using TGR-1202 and lenalidomide in combination
with the antibody, obinutuzumab?
Basic Study Information
Purpose:Location: Cancer Center
This phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide,
or combination chemotherapy work in treating patients with grade I-IIIa follicular
lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
Immunotherapy with obinutuzumab, may induce changes in body's immune system and may
interfere with the ability of tumor cells to grow and spread. Umbralisib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Biological therapies, such as lenalidomide, use substances made from living organisms
that may stimulate or suppress the immune system in different ways and stop cancer
cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin,
vincristine, prednisone, and bendamustine, work in different ways to stop the growth
of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving obinutuzumab with
or without umbralisib, lenalidomide, or combination chemotherapy will work better
in treating patients with grade I-IIIa follicular lymphoma.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03269669?term=S1608&rank=1
Study Reference #: CLYM17097
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Lauren Mitchell
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search